



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated November 27, 2018

To,
National Stock Exchange of India Limited,
BSE Limited
Symbol: GRANULES Scrip Code: 532482

Sub: Received approval for ANDA filed by Granules Pharmaceuticals, Inc..

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc., subsidiary of Granules India Limited, through its US agent First Time US Generics LLC, for Methylphenidate Hydrochloride Extended-Release Tablets USP, 10 mg and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug "Ritalin SR Sustained-Release Tablets, 20 mg" of Novartis Pharmaceuticals Corporation. Granules Pharmaceuticals, Inc. shall market and distribute the product shortly.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

FOR GRANULES INDIA LIMITED



CHAITANYA TUMMALA
COMPANY SECRETARY
COMPLIANCE OFFICER